AcuCort Enters Licensing, Distribution Deal for Zeqmelit Drug in Canada

05:51 AM EST, 11/09/2026 (MT Newswires) -- AcuCort (ACUC.ST) granted Kye Pharmaceuticals the exclusive rights to register, market, distribute, and sell Zeqmelit, its rapidly dissolving dexamethasone oral film, in Canada. The Swedish pharmaceutical company will receive upfront and milestone payments, product supply revenue, and net sales-based royalties as part of the license and distribution agreement, according to a Monday release. Regulatory submission is targeted for early 2027, and commercial launch is expected in 2028, subject to marketing authorization from Health Canada. Zeqmelit is indicated for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for patients with COVID-19 requiring supplemental oxygen therapy.